Results 11 to 20 of about 693,900 (279)
PARP inhibitors in ovarian cancer [PDF]
Annals of Oncology, 2016 Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. Poly(ADP-ribose) polymerase (PARP) inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway.
Ledermann, JA
openaire +5 more sources
Advances in the use of PARP inhibitor therapy for breast cancer [PDF]
Drugs in Context, 2018 Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj +2 more sources
PARP inhibitors: the race is on [PDF]
British Journal of Cancer, 2016 Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 (BRCA1/2) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition (Bryant et al, 2005; Farmer et al, 2005), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific ...
Brown, Jessica S +2 more
openaire +2 more sources
PARP inhibitors combined with radiotherapy: are we ready?
Frontiers in Pharmacology, 2023 PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in cancer treatment.
Chen Sun +6 more
doaj +1 more source
Molecular Oncology, 2022 Poly[ADP‐ribose] polymerase (PARP) inhibitors can block DNA single‐strand damage repair and subsequently increase double‐stranded breaks (DSBs) by reducing the activity of the PARP1 protease and by preventing the PARP1 protein from dissociating from ...
Xiang Cheng +4 more
doaj +1 more source
A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer
Сибирский онкологический журнал, 2022 Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht +4 more
doaj +1 more source
Annals of Internal Medicine: Clinical Cases, 2023 Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto +5 more
doaj +1 more source
The Journal of Clinical Investigation, 2022 Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu +21 more
doaj +1 more source